Bladder cancer: radiation and hyperthermia chemo after operation in depth next to blaaskankerpatienten (T1 and T2) with increased risk of relapse gives good results on overall survival and disease-free time historically compared without hyperthermia. Article update 1 August 2011
Please read the warning for Dr. Robert Gorter and Cologne's Medical Center. Dr. Robert Gorter is discredited hit in Germany and Egypt and also we distance ourselves from Dr. Robert Gorter. Click here or below questions for comprehensive explanation why we Dr. Robert Gorter no longer find reliable doctor.
October 31, 2009: source: Radiotherapie and Oncology by m. Wittlinger, et al., from the Department of Radiation Oncology of the prestigious Erlangen University Medical School in Germany. Radiotherapie and Oncology is the official publication of the European Society for Therapeutic Radiology and Oncology.
Hyperthermia in addition to radiotherapy and chemotherapy after operation makes blaaskankerpatienten with T1 and T2 at stage and with a high risk of relapse for better overall survival and disease-free time than longer without hyperthermia. Hyperthermia equipment that was used with the antenna system of BSD. Side effects (e.g. incineration) grade 3/4 occurred at 24% of the patients were given for that hyperthermia. The study was conducted and analyzed at 45 blaaskankerpatienten with increased risk of relapse in the period 2003 to 2007. 1 time per week was after the surgery and the bestralingchemotherapie performed a so-called depth hyperthermia. the difference with 5 to 7 weeks in comparable statistical figures without hyperthermia blaaskankerpatienten would be thus BSD (producer of the used hyperthermia equipment) on their website and thus not the researchers of this study: (82% vs. 67% after 5 years) locale tumor control (81% vs. 63% after 3 years). We suspect that BSD the figures a bit rosier than in reality because on their website they write also about a significant difference while the researchers do not use that Word and only conclude that the results are encouraging. In addition, the study also no randomized study was therefore in such a study not be signaled signicante differences can. Below we have an abstract abstract of hyperthermia study of cisplatin and 5-FU after operation placed and in combination with irradiation at high risk blaaskankerpatienten and the differences in overall survival differences with that of the hyperthermia group was 80% in hyperthermia group versus 72% survival without relapse after 5 years in the cisplatin-5FU group. 8% difference and with less side effects is a fine result of course.
Results:
